250 related articles for article (PubMed ID: 36129622)
21. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
[TBL] [Abstract][Full Text] [Related]
22. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
23. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
24. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
Cavaletti G; Cornblath DR; Merkies ISJ; Postma TJ; Rossi E; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; ; Mazzeo A; Pace A; Pessino A; Schenone A; Toscano A; Argyriou AA; Brouwer B; Frigeni B; Piras B; Briani C; Dalla Torre C; Dominguez Gonzalez C; Faber CG; Tomasello C; Binda D; Brandsma D; Cortinovis D; Psimaras D; Ricard D; Storey D; Cornblath DR; Galiè E; Lindeck Pozza E; Rossi E; Vanhoutte EK; Lanzani F; Pastorelli F; Altavilla G; Cavaletti G; Granata G; Kalofonos HP; Ghignotti I; Merkies ISJ; Bruna J; Hense J; Heimans JJ; Mattavelli L; Padua L; Reni L; Bakkers M; Boogerd M; Campagnolo M; Cazzaniga M; Eurelings M; Leandri M; Lucchetta M; Penas Prado M; Russo M; Valsecchi MG; Piatti ML; Alberti P; Bidoli P; Grant R; Plasmati R; Velasco R; Lalisang RI; Meijer RJ; Fabbri S; Dorsey SG; Galimberti S; Kerrigan S; Koeppen S; Postma TJ; Boogerd W; Grisold W
Ann Oncol; 2013 Feb; 24(2):454-462. PubMed ID: 22910842
[TBL] [Abstract][Full Text] [Related]
25. Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.
Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB
J Natl Compr Canc Netw; 2024 Feb; 22(2):108-116. PubMed ID: 38364373
[TBL] [Abstract][Full Text] [Related]
26. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
[TBL] [Abstract][Full Text] [Related]
27. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
29. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
30. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
31. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
32. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Salgado TM; Liu J; Reed HL; Quinn CS; Syverson JG; Le-Rademacher J; Lopez CL; Beutler AS; Loprinzi CL; Vangipuram K; Smith EML; Henry NL; Farris KB; Hertz DL
Breast; 2020 Jun; 51():21-28. PubMed ID: 32193049
[TBL] [Abstract][Full Text] [Related]
33. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
34. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
35. Assessment of sudomotor function in hypertensive with/without type-2 diabetes patients using SUDOSCAN: An electrophysiological study.
Hussein II; Alshammary SHA; Al-Nimer MSM
Clin Neurophysiol Pract; 2021; 6():22-28. PubMed ID: 33490739
[TBL] [Abstract][Full Text] [Related]
36. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
[TBL] [Abstract][Full Text] [Related]
37. Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy.
Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG
JCO Precis Oncol; 2024 Apr; 8():e2300690. PubMed ID: 38691814
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.
Vasquez S; Guidon M; McHugh E; Lennon O; Grogan L; Breathnach OS
Ir J Med Sci; 2014 Mar; 183(1):53-8. PubMed ID: 23832573
[TBL] [Abstract][Full Text] [Related]
40. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
